Dougenis D, Brown A H
Department of Surgery, Patras University School of Medicine, Greece.
Heart. 1998 Jul;80(1):9-13. doi: 10.1136/hrt.80.1.9.
To evaluate the long term results of coronary reoperations for recurrent angina with internal mammary (thoracic) arteries versus vein grafts.
Inception cohort of 103 patients with a mean follow up of 7.1 years (range 1.0-11.6).
Regional cardiothoracic centre.
Among 103 consecutive patients, mean (SD) age 61.8 (9.7) years, who were reoperated for recurrent angina between January 1982 and December 1991, 53 patients had unilateral or bilateral internal mammary artery (IMA) grafting supplemented or not with saphenous vein (SV) grafts (group A), and 50 patients underwent reoperative coronary surgery using SV grafts only (group B). The two groups were comparable in terms of demographic and clinicopathological data.
Operative mortality was 5.6% (95% confidence interval 4.6 to 6.6) for group A, and 10% (8.2 to 11.8) for group B (p > 0.05). Probability of freedom from new recurrence of angina was 86% at 5 and 10 years in group A, compared with 56% and 25% respectively in group B (p = 0.005). Freedom from cardiac events was estimated to be 81% at 5 and 10 years in group A, v 52% and 20% for group B, respectively. Actuarial survival was 95% v 93% at 3 years, 95% v 85% at 5 years, and 88% v 71% at 10 years after reoperation (p > 0.05).
The long term results of IMA are superior to SV grafts in terms of freedom from new recurrence of angina and other cardiac events. The IMA is thus the conduit of choice in coronary revascularisation.
评估采用乳内(胸廓)动脉与静脉移植物进行冠状动脉再次手术治疗复发性心绞痛的长期效果。
起始队列研究,共103例患者,平均随访7.1年(范围1.0 - 11.6年)。
地区心胸中心。
在1982年1月至1991年12月期间因复发性心绞痛接受再次手术的103例连续患者中,平均(标准差)年龄61.8(9.7)岁,53例患者进行了单侧或双侧乳内动脉(IMA)移植,辅以或不辅以大隐静脉(SV)移植(A组),50例患者仅使用SV移植物进行再次冠状动脉手术(B组)。两组在人口统计学和临床病理数据方面具有可比性。
A组手术死亡率为5.6%(95%置信区间4.6至6.6),B组为10%(8.2至11.8)(p>0.05)。A组在5年和10年时无新的心绞痛复发概率分别为86%,而B组分别为56%和25%(p = 0.005)。A组在5年和10年时无心脏事件概率估计分别为81%,B组分别为52%和20%。再次手术后3年时实际生存率为95%对93%,5年时为95%对85%,10年时为88%对71%(p>0.05)。
就无新的心绞痛复发及其他心脏事件而言,IMA的长期效果优于SV移植物。因此,IMA是冠状动脉血运重建的首选管道。